Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclosporine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA known ✓ | P62937 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 13/20 | 1.00 |
| ▸ | PPP3CA | Q08209 | 3/20 | 1.00 |
| ▸ | FKBP1B | P68106 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
| ▸ | PPIB | P23284 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclosporine SCHEMBL21170318 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23382247 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239446 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24224445 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL25083206 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239035 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192320 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23110210 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239036 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192319 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240035-A2 | CONJUGATE TARGETING CARDIOVASCULAR DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| US-20220401362-A1 | LIPID NANO DRUG DELIVERY SYSTEM TARGETING BRAIN LESION AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Second Medical Investment Management Co. Ltd (CN) | 2022-12-22 | — | — | US | claimed |
| EP-4062940-A1 | LIPID NANO DRUG DELIVERY SYSTEM TARGETING BRAIN LESION AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-09-28 | — | — | EP | claimed |
| EP-3103468-B1 | PREVENTION OF DRUG-ASSOCIATED KERATOCONJUNCTIVITIS WITH A CYCLOSPORIN | ALLERGAN INC (US) | 2020-07-15 | — | — | EP | claimed |
| EP-2845602-B1 | CYCLOSPORINE-CONTAINING, NON-IRRITATIVE NANOEMULSION OPTHALMIC COMPOSITION | INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIV (KR) | 2017-10-11 | — | — | EP | claimed |
| EP-2153842-B1 | PREVENTION OF DRUG-ASSOCIATED KERATOCONJUNCTIVITIS WITH A CYCLOSPORIN | ALLERGAN INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2376103-B1 | CYCLOSPORINE COMPOSITIONS FOR ENHANCING NAIL GROWTH | ALLERGAN INC (US) | 2012-12-12 | — | — | EP | claimed |
| EP-1104296-B1 | BIOIMPLANT FORMULATION | PEPTECH ANIMAL HEALTH PTY LTD (AU) | 2012-06-13 | — | — | EP | claimed |
| EP-1929996-B1 | Ophthalmic emulsions containing an immunosuppressive agent | NOVAGALI PHARMA SA (FR) | 2011-02-16 | — | — | EP | claimed |
| EP-1893573-B1 | INHIBITORS OF HCV REPLICATION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| EP-1054685-B1 | LIQUID CRYSTAL FORMS OF CYCLOSPORIN | INHALE THERAPEUTIC SYST (US) | 2001-11-28 | — | — | EP | claimed |
| EP-1140135-A1 | CYCLOSPORIN SOLUTION | ratiopharm GmbH (DE) | 2001-10-10 | — | — | EP | claimed |
| EP-0759773-B1 | LACRIMAL GLAND SPECIFIC EMULSIONS FOR TOPICAL APPLICATION TO OCULAR TISSUE | ALLERGAN SALES INC (US) | 2001-08-08 | — | — | EP | claimed |
| EP-0650721-B1 | Cyclosporin soft capsule | HANMI PHARM IND CO LTD (KR) | 2000-09-13 | — | — | EP | claimed |
| WO-2000038702-A1 | CYCLOSPORIN SOLUTION | RATIOPHARM GMBH (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0539319-B1 | Pharmaceutical cyclosporin composition | NOVARTIS AG (CH) | 1999-12-08 | — | — | EP | claimed |
| EP-0642332-B1 | OPHTHALMIC COMPOSITIONS CONTAINING A CYCLOSPORIN | SANDOZ LTD (CH) | 1997-01-15 | — | — | EP | claimed |
| EP-0607258-B1 | USE OF IFN-GAMMA FOR THE TREATMENT OF INFECTIONS IN TRANSPLANT RECIPIENTS | GENENTECH INC (US) | 1997-01-02 | — | — | EP | claimed |
| EP-0487289-B1 | Cyclosporin immunoassay | BEHRINGWERKE AG (DE) | 1996-09-04 | — | — | EP | claimed |